65,437 trials
Anal Cancer
Primary: Percentage of Subjects With Acute Gastrointestinal (GI) and Genitourinary (GU) Adverse Events (AE) ≥ Grade 2 as Defined by CTCAE v3.0 (Common Terminology Criteria for…
Sinusitis
Primary: Change in Computed Tomography (CT) Score After Treatment — -.64; -.63; -.5; -.5 units on a scale
Chronic Obstructive Pulmonary Disease
Primary: Exercise Endurance Time — 490; 333; 472; 362 seconds — p=< 0.05
Autism
Primary: Change in TNF-alpha Levels — 57 mean % change
Meningitis · Meningococcal Meningitis · Meningococcal Infections
Primary: Number of Participants With Serum Bovine Albumin Baby Rabbit (SBA-BR) Titers of >=1:128 Following Vaccination With One Dose of Menactra® Vaccine — 177; 2; 4; 154…
Malaria · Plasmodium Falciparum
Primary: Number of Participants Infected — 5; 3; 6 Participants
Diabetes Mellitus, Type 2 · Renal Insufficiency
Primary: Change in HbA1c From Baseline to Week 26 — -0.03; -0.33; -0.44 Percent — p=0.012
Malaria
Primary: Number of Subjects With Serious Adverse Events (SAEs). — 38; 28; 33 subjects
Diabetes · Hypoglycemia
Primary: Hypoglycemia Incidence — 53; 10 participants — p=<0.001
Pain, Postoperative
Primary: Postoperative Cumulative Fentanyl Consumption — 836 mcg
Neuromuscular Monitoring After Administration of Neuromuscular Blocking Agents in Different Types of Surgery
Primary: Number of Participants With a Train-Of-Four (TOF)-Ratio <0.9 at Extubation — 55; 17; 95 participants
Melanoma · Malignant Melanoma · Melanoma, Experimental
Primary: Clinical Response — 1; 3; 3; 2 Participants
Diabetes Mellitus
Primary: Change From Baseline in Postprandial Incremental Area Under the Curve for Total Triglycerides at Week 16. — -39.728; -346.957; -293.439 mg.h/dL — p=<0.001
Arthritis, Psoriatic
Primary: Percentage of Participants With at Least 1 Serious Adverse Event (SAE): Baseline up to Year 1 — 7.97 Percentage of participants
HIV Infection
Primary: Mean Change From Baseline Plasma HIV RNA (Log Copies/mL) — 5.4 log copies/mL plasma